The deferiprone controversy: time to move on.

The Editor has asked me to comment on the report[1][1] issued by the Canadian Association of University Teachers (CAUT) on the controversy surrounding the trials of the iron-chelation drug deferiprone (L1) at the Hospital for Sick Children (HSC). The CAUT Inquiry report is yet another in a series

[1]  C. Naylor.  Early Toronto experience with new standards for industry-sponsored clinical research: a progress report. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[2]  L. Thomas.  On the science and technology of medicine. , 1988, Daedalus.

[3]  J. Knowles.  Doing Better and Feeling Worse , 1978 .